Switzerland· 68609001
Opdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml), Konzentrat zur Herstellung einer Infusionslösung
A nivolumab and relatlimab product containing relatlimabum, nivolumabum, registered in Switzerland by Bristol-Myers Squibb SA and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Nivolumab and relatlimab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FY02 (nivolumab and relatlimab), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Nivolumab and relatlimab · ATC L01FY02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- relatlimabum, nivolumabum
- Manufacturer
- Bristol-Myers Squibb SA
- Country
- Switzerland (CH)
- ATC code
- L01FY02
- ATC class
- Nivolumab and relatlimab
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680686090019Durchstf 20 mlCHF 5960.15
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nivolumab and relatlimab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaOPDUALAGBRISTOL-MYERS SQUIBB CANADA
- CzechiaOPDUALAGBristol-Myers Squibb Pharma EEIG, Dublin
- SpainOPDUALAG 240 MG/80 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- FinlandOpdualagBristol-Myers Squibb Pharma EEIG
- FranceOPDUALAG 240 mg/80 mg, solution à diluer pour perfusionBRISTOL-MYERS SQUIBB / PFIZER EEIG (IRLANDE)
- United KingdomOpdualag 240mg/20ml / 80mg/20ml concentrate for solution for infusion vialsBristol-Myers Squibb Pharmaceuticals Ltd
- IrelandOpdualag 240 mg/80 mg sterile concentrateBristol-Myers Squibb Pharma EEIG
- IcelandOpdualagBristol-Myers Squibb Pharma EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Opdualag
- Liechtenstein · Opdualag
- Norway · Opdualag
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f8be2901-24aa-46b4-9f0f-606178c9419c GET /v1/drugs/f8be2901-24aa-46b4-9f0f-606178c9419c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "relatlimabum 80 mg + nivolumabum 240 mg",
"valid_from": "2024-02-01",
"limitations": "[{\"description\":\"OPDUALAG ist für die Erstlinienbehandlung von Erwachsenen mit nicht resezierbarem oder metastasiertem Melanom mit einer PD-L1-Expression < 1% indiziert.<br>\\nBristol Myers Squibb erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, für jede bezogene Packung einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21515.01<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21515.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-01-01\",\"validTo\":\"2027-01-31\"}]",
"galenic_form": "Inf Konz",
"therapeutic_area": null,
"sl_inclusion_date": "2024-02-01",
"self_retention_pct": 10
}See everything about nivolumab and relatlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.